News

BASF & CSM form joint venture
Enlarge image

BusinessGermanyNetherlands

BASF & CSM form joint venture

08.10.2012 - German chemicals giant and Dutch CSM daughter Purac have formed a
50/50 joint venture to produce and market biobased succinic acid.

The largest chemical firm of the world, BASF SE (Ludwigshafen, Gemany), and the leading producer of biobased lactic acid, Purac NV (Diemen, The Netherlands), a subsidiary of Dutch CSM, have formed a joint venture. After three years of testing of a novel fermentation process on pre-industrial scale at Purac’s production site in Montmélo near Barcelona, Succinity GmbH is going to start the production and sale of biobased succinic acid from 2013 . Succinity, which will be headquartered in Düsseldorf Germany, will be the third player in the market for biologically produced succinic acid, an important chemical building block for making 1,4-butanediol (1,4-BDO), tetrahydrofuran (THF) and gamma-butyrolactone (GBL). These bulk chemicals are needed for making polyesters, polyurethanes, spandex and biodegradable plastics with a global market value of more than $4bn.

BASF and CSM are currently expand Purac’s fermentation facility to deliver an annual capacity of 10,000 metric tons of succinic acid from late 2013. This is complemented by plans for a second large-scale facility with an annual capacity of 50,000 metric tons of succinic acid to enable the company to respond to the expected increase in demand. The final investment decision for this facility will be made following a successful market introduction, according to the companies.

Despite stiff competition from Reverdia, a joint-venture of Dutch DSM and French Roquette, and US-headquartered BioAmber Inc., BASF wants to take a leading position in the market. „The market is large enough for all players“, said BASF spokesman Holger Kapp to EuroBiotechNews. Earlier this year, Reverdia announced it will start biosuccinate production at the end of 2012. At the beginning of 2011, BioAmber had already started production of 2,000 metric tons of biosuccinate at its French production site in Pomacle and has since then expanded its production and its capacities to produce 1,4-BDO. However, BASF has brought in a unique production technology. Its proprietary microorganism Basfia succiniciproducens can make  biobased succinic acid either from plant-made sugars or by glycerol, a waste product form biodiesel production. This might give Succinity a competitive edge over the competitor’s technologies that can only convert crop- or plant-made sugars.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/basf-csm-form-joint-venture.html

PoliticsFranceUKSweden

24.04.2015 AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.

PoliticsEU

22.04.2015 A legislative proposal by the European Commission is set to renationalise market authorisation of genetically modified crops.

FinancingUK

21.04.2015 Ahead of its listing on the London Stock Exchange, Woodford’s Patient Capital Trust has raised a record sum of €1.1bn. The fund met with immense interest by investors.

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DBelgium

14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.

Stock MarketsEUFranceUKNorwaySweden

09.04.2015 The European public markets remain highly attractive for biotech companies. Twice as many companies went public in the first quarter of 2015 than during the same period last year.

FinancingAustriaUKSwitzerlandGermany

08.04.2015 To bring its lead product of a new class of antimicrobials to phase 3 trials, Nabriva Therapeutics has completed a US$120m Series B financing.

Research & DevelopmentNetherlands

07.04.2015 Gene therapy is attracting more and more big pharma companies. Now, Bristol-Myers Squibb has forged a US$1bn collaboration with Dutch uniQure, also picking up a 4.9% share in the company.

Stock MarketsFrance

02.04.2015 Sensorion is the latest French biotech to go public, following a spate of IPOs on Paris Euronext. The biopharma plans for a €12m IPO to finance its pipeline of inner ear disease drugs.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • WILEX3.59 EUR5.59%
  • BASILEA118.10 CHF3.14%
  • PAION2.58 EUR2.79%

FLOP

  • BIOTEST79.20 EUR-19.51%
  • CYTOS1.01 CHF-8.18%
  • FORMYCON28.00 EUR-6.01%

TOP

  • CO.DON3.15 EUR22.1%
  • WILEX3.59 EUR21.3%
  • FORMYCON28.00 EUR21.0%

FLOP

  • CYTOS1.01 CHF-27.9%
  • BIOTEST79.20 EUR-18.1%
  • THERAMETRICS0.07 CHF-12.5%

TOP

  • SANTHERA98.85 CHF2460.9%
  • CYTOS1.01 CHF676.9%
  • WILEX3.59 EUR337.8%

FLOP

  • MOLOGEN5.07 EUR-54.8%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.41 EUR-28.1%

No liability assumed, Date: 26.04.2015